02.07.19 | news
Endpoints – Arch joins Celgene, China investors bankrolling a pioneering New York biotech startup focused on a new approach to metastasis
Julio Aguirre-Ghiso has steered the work in his lab at Mount Sinai down some of the less-traveled pathways of cancer research. And it’s led him to launch a biotech — which is having its coming-out party today in New York — that has now set out to develop new medicines tailored for the field he’s been pioneering.
Read full story by John Carroll here.